Options
Clinical Evaluation of Proline, Glutamic acid, and Leucine-Rich Protein 1 Expression in Astrocytomas and Correlations with the Proliferation Marker Ki-67
Date Issued
01-04-2021
Author(s)
Padmavathy, Karthika P.
Vuttaradhi, Veena Kumari
Venu, Akkanapally
D’Cruze, Lawrence
Saravanan, Roshni
Pitani, Ravishankar
Ganesh, Krishnamurthy
Pacharla, Himavani
Indian Institute of Technology, Madras
Prathiba, D.
Venkatraman, Ganesh
Abstract
Malignant astrocytomas presenting in humans of any age group are a challenge to diagnose and treat. Hence, there is a quest for new markers to ascertain their grades and predict disease outcomes. Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a nuclear receptor co-regulator, is an oncogene found in various cancers. We postulate that by screening for PELP1, its correlation with survival outcomes of patients across various grades can indicate a plausible novel diagnostic marker and a potential therapeutic target in gliomas. Immunostaining of 100 cases of astrocytomas for PELP1 was performed on paraffin-embedded sections. Results showed that PELP1 expression increases with higher grades; the mean H-score of PELP1 in grade-I astrocytomas was determined to be 112.3, whereas in grade-IV it was 235.1 (P value = 0.0001). Survival analysis of patients with H-score of 200–300 was only 8.8% and 68.8% in patients with scores of 0–100. PELP1 expression in high-grade astrocytomas is an important factor in determining the outcomes. [Figure not available: see fulltext.]
Volume
71